CN101553487B - 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 - Google Patents

取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 Download PDF

Info

Publication number
CN101553487B
CN101553487B CN2007800395790A CN200780039579A CN101553487B CN 101553487 B CN101553487 B CN 101553487B CN 2007800395790 A CN2007800395790 A CN 2007800395790A CN 200780039579 A CN200780039579 A CN 200780039579A CN 101553487 B CN101553487 B CN 101553487B
Authority
CN
China
Prior art keywords
dimethoxy
pyrido
hexahydro
isobutyl
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800395790A
Other languages
English (en)
Chinese (zh)
Other versions
CN101553487A (zh
Inventor
凯尔·W·加诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101553487(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN101553487A publication Critical patent/CN101553487A/zh
Application granted granted Critical
Publication of CN101553487B publication Critical patent/CN101553487B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2007800395790A 2006-11-08 2007-11-08 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法 Active CN101553487B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
US60/864,944 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (2)

Publication Number Publication Date
CN101553487A CN101553487A (zh) 2009-10-07
CN101553487B true CN101553487B (zh) 2012-06-13

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800395790A Active CN101553487B (zh) 2006-11-08 2007-11-08 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法

Country Status (16)

Country Link
US (2) US8039627B2 (https=)
EP (1) EP2081929B1 (https=)
JP (1) JP5290185B2 (https=)
KR (1) KR101500766B1 (https=)
CN (1) CN101553487B (https=)
AU (1) AU2007317242B2 (https=)
BR (1) BRPI0718247B1 (https=)
CA (1) CA2668689C (https=)
DK (1) DK2081929T3 (https=)
EA (1) EA018378B1 (https=)
ES (1) ES2402220T3 (https=)
IL (1) IL198250A0 (https=)
MX (1) MX2009004910A (https=)
PL (1) PL2081929T3 (https=)
PT (1) PT2081929E (https=)
WO (1) WO2008058261A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EA202091397A1 (ru) * 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
HK1221645A1 (zh) * 2013-09-27 2017-06-09 Auspex Pharmaceuticals, Inc. Vmat2的苯并喹啉抑制剂
EA201791466A1 (ru) * 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
CA2974540C (en) * 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
EA036837B1 (ru) * 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
MX383906B (es) 2015-10-09 2025-03-14 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
MY193767A (en) * 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) * 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10479787B2 (en) 2016-04-22 2019-11-19 Lupin Limited Process for preparation of tetrabenazine and deutetrabenazine
US10442800B2 (en) * 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
EP3523300A1 (en) 2016-10-06 2019-08-14 Assia Chemical Industries Ltd. Solid state forms of valbenazine
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
EP3713938A1 (en) 2017-11-22 2020-09-30 Assia Chemical Industries Ltd Solid state form of valbenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) * 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US12565495B2 (en) * 2019-08-12 2026-03-03 Luye Innomind Pharma Shijiazhuang Co., Ltd. VMAT2 inhibitor and preparation method therefor and application thereof
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2022547990A (ja) 2019-09-13 2022-11-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジンの合成のための方法
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
PT4168409T (pt) 2021-03-22 2025-06-12 Neurocrine Biosciences Inc Inibidores de vmat2 e métodos de utilização
US20240239791A1 (en) 2021-04-26 2024-07-18 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
BR112023026691A2 (pt) 2021-06-30 2024-03-05 Neurocrine Biosciences Inc Valbenazina para uso no tratamento complementar de esquizofrenia
MX2023014977A (es) 2021-06-30 2024-02-09 Neurocrine Biosciences Inc Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
WO2023172849A1 (en) 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
TW202421131A (zh) 2022-09-21 2024-06-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑及其使用方法
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of huntington's chorea
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2852518A (en) * 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
WO2007005283A2 (en) 2005-06-29 2007-01-11 Trustees Of Columbia University In The City Of New York Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP1855677B1 (en) 2005-08-06 2008-12-03 Cambridge Laboratories (Ireland) Limited 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aranda,G. et al..Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine.《Eur. J. Med. Chem.》.1990,第25卷(第4期),369-374. *
Brossi,A. et al..Syntheseversuche in der Emetin-Reihe.《Helvetica Chimica Acta》.1958,第41卷(第4期),1793-1806. *
Kilbourn,M.R. et al..Absolute Configuration of (+)-a-Dihydrotetrabenazine, an Active Metabolite of Tetrabenazine.《Chirality》.1997,第9卷(第1期),59-62. *

Also Published As

Publication number Publication date
AU2007317242B2 (en) 2013-08-01
ES2402220T3 (es) 2013-04-29
KR101500766B1 (ko) 2015-03-16
US8039627B2 (en) 2011-10-18
EP2081929B1 (en) 2013-01-09
IL198250A0 (en) 2009-12-24
US8357697B2 (en) 2013-01-22
KR101500766B9 (ko) 2024-09-25
CA2668689A1 (en) 2008-05-15
PT2081929E (pt) 2013-04-15
JP2010509366A (ja) 2010-03-25
CN101553487A (zh) 2009-10-07
DK2081929T3 (da) 2013-04-15
AU2007317242A1 (en) 2008-05-15
EP2081929A1 (en) 2009-07-29
PL2081929T3 (pl) 2013-06-28
MX2009004910A (es) 2009-07-24
EA200970461A1 (ru) 2009-12-30
WO2008058261A1 (en) 2008-05-15
ES2402220T8 (es) 2021-12-23
BRPI0718247A2 (pt) 2014-01-07
US20120077839A1 (en) 2012-03-29
CA2668689C (en) 2015-12-29
KR20090079257A (ko) 2009-07-21
BRPI0718247B1 (pt) 2021-09-21
US20080167337A1 (en) 2008-07-10
EA018378B1 (ru) 2013-07-30
JP5290185B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
CN101553487B (zh) 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
JP2025081429A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
US20150071918A1 (en) Peptides for the treatment of cancer
US20090156671A1 (en) Deuterium-enriched oxybutynin
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
EP1638934B1 (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
EP1120416A1 (en) Pyrido[2.3-b][1,4]benzodiazepinones as M2 receptor ligand for the treatment of neurological disorders
US6825193B2 (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
US20240327372A1 (en) Preparation of phenethylamines and cathinones and stereoisomers thereof and precursors thereof
EP3980401B1 (en) Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
RU2840772C1 (ru) Замещенные пиперидиновые соединения и их применение
WO2018023009A1 (en) Deuterated lurasidone
US20090062331A1 (en) Deuterium-enriched maraviroc
CN121532384A (zh) 嘧啶化合物及其作为usp1抑制剂的用途
HK40129633A (zh) 苯乙胺和卡西酮及其立体异构体与其前体的制备
EP1501793A1 (en) Tamsulosin derivative
IL324923A (en) Asymmetric phenylalkylamines
US20220306637A1 (en) Imidazopyrazine Derivatives and the Use Thereof as Medicament
Muth Design, Synthesis, and Biological Evaluation of Novel Polyamine Transport System Probes and Their Application to Human Cancers
US20220064122A1 (en) Analogs of Dextromethorphan with Balanced Receptor Activities
CA3008653A1 (en) Bruton's tyrosine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Gano Kyle W.

Inventor after: Nichol Harriot

Inventor before: Gano Kyle W.